^
Association details:
| Biomarker: | HOXA9 overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | entospletinib (GS-9973) (SYK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Entospletinib in Combination With Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 expression
Published date:
08/20/2020
Excerpt:
The composite complete response with entospletinib + 7+3 was 70%....Improved survival was observed in patients with HOXA9/MEIS1 overexpression, contrasting published data demonstrating poor survival in such patients.
DOI:
10.1158/1078-0432.CCR-20-1064
